Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C15H13NO3 |
Molecular Weight | 255.2686 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)[C@@H]1CCN2C1=CC=C2C(=O)C3=CC=CC=C3
InChI
InChIKey=OZWKMVRBQXNZKK-LLVKDONJSA-N
InChI=1S/C15H13NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13/h1-7,11H,8-9H2,(H,18,19)/t11-/m1/s1
Molecular Formula | C15H13NO3 |
Molecular Weight | 255.2686 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
(R)- enantiomer does not exhibit COX inhibition – it was > 100-fold less active than (S)- enantiomer on both COX subtypes. (R)- enantiomer is about 60 times less potent than the (-)-S isomer in the carrageenan edema test and ca. 230 times less active than the (-)-S isomer in the mouse phenylquinone writhing assay. R-ketorolac is an inhibitor of fatty acid amide hydrolase, but not at physiological concentrations.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9549656 |
34.0 nM [IC50] | ||
Target ID: CHEMBL2243 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9989926 |
50.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Absolute configuration of (-)-5-benzoyl-1,2-dihydro-3H-pyrrolo[1,2-alpha]pyrrole-1-carboxylic acid, the active enantiomer of ketorolac. | 1986 Apr |
|
Determination of ketorolac enantiomers in plasma using enantioselective liquid chromatography on an alpha 1-acid glycoprotein chiral stationary phase and ultraviolet detection. | 1994 Aug 5 |
|
Racemization of ketorolac in aqueous solution. | 1995 Sep |
|
Preclinical enantioselective pharmacology of (R)- and (S)- ketorolac. | 1998 Feb |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10422661
Rat: 60,120 or 200 ug
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9549656
(R)-ketorolac showed 12% inhibition of [3H]pCl-Phe-DPDPE binding to delta opioid receptor at 10(-5) M.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:18:31 GMT 2023
by
admin
on
Sat Dec 16 11:18:31 GMT 2023
|
Record UNII |
10A5O25ILE
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
66635-93-6
Created by
admin on Sat Dec 16 11:18:31 GMT 2023 , Edited by admin on Sat Dec 16 11:18:31 GMT 2023
|
PRIMARY | |||
|
76227
Created by
admin on Sat Dec 16 11:18:31 GMT 2023 , Edited by admin on Sat Dec 16 11:18:31 GMT 2023
|
PRIMARY | |||
|
10A5O25ILE
Created by
admin on Sat Dec 16 11:18:31 GMT 2023 , Edited by admin on Sat Dec 16 11:18:31 GMT 2023
|
PRIMARY | |||
|
181818
Created by
admin on Sat Dec 16 11:18:31 GMT 2023 , Edited by admin on Sat Dec 16 11:18:31 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
RACEMATE -> ENANTIOMER |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||